Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of $7.45 million. The enterprise value is -$2.92 million.
| Market Cap | 7.45M |
| Enterprise Value | -2.92M |
Important Dates
The last earnings date was Friday, November 14, 2025, before market open.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 911.04 million shares outstanding. The number of shares has increased by 106.88% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 911.04M |
| Shares Change (YoY) | +106.88% |
| Shares Change (QoQ) | +66.48% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 4.73% |
| Float | 1.73B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.23 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.78 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -10.48% and return on invested capital (ROIC) is -10.02%.
| Return on Equity (ROE) | -10.48% |
| Return on Assets (ROA) | -8.48% |
| Return on Invested Capital (ROIC) | -10.02% |
| Return on Capital Employed (ROCE) | -15.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$361,222 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.75% in the last 52 weeks. The beta is -0.74, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.74 |
| 52-Week Price Change | -82.75% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 53.63 |
| Average Volume (20 Days) | 292,549 |
Short Selling Information
| Short Interest | 454,974 |
| Short Previous Month | 2.84M |
| Short % of Shares Out | 31.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | -62,000 |
| Operating Income | -5.03M |
| Pretax Income | -3.27M |
| Net Income | -3.25M |
| EBITDA | -4.99M |
| EBIT | -5.03M |
| Earnings Per Share (EPS) | -$0.01 |
Balance Sheet
The company has $10.45 million in cash and $256,000 in debt, giving a net cash position of $10.20 million or $0.01 per share.
| Cash & Cash Equivalents | 10.45M |
| Total Debt | 256,000 |
| Net Cash | 10.20M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 32.82M |
| Book Value Per Share | 0.04 |
| Working Capital | 4.72M |
Cash Flow
| Operating Cash Flow | -6.60M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.60M |
| FCF Per Share | -$0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -106.88% |
| Shareholder Yield | -106.88% |
| Earnings Yield | -43.62% |
| FCF Yield | -88.60% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 17, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |